secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0000950170-23-010933
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Biosciences FY2022 revenue up 47% to $9.96M; net loss per share improves to $25.65 from $27.56
--------------------------------------------------------------------------------

- Total revenues $9.956M, up 47% YoY; Q4 revenue $1.0M, down 54% YoY.
- Operating expenses $28.771M, down 32% YoY; cash used in operations $13.977M, down 46%.
- Net loss attributable to common stockholders $15.376M ($25.65/share) vs $14.660M ($27.56/share) in 2021.
- GoodWheat pasta launched in Q2 2022, reached 1,200+ stores within 7 months; AHA Heart-Check certified.
- CEO Stan Jacot appointed in Q1 2022; Project Greenfield 3-year plan for profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017023010933/0000950170-23-010933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017023010933/rkda-20230330.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer